---
document_datetime: 2025-12-29 08:35:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/verkazia.html
document_name: verkazia.html
version: success
processing_time: 0.1142195
conversion_datetime: 2025-12-30 00:16:16.688635
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Verkazia

[RSS](/en/individual-human-medicine.xml/67074)

##### Authorised

This medicine is authorised for use in the European Union

ciclosporin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Verkazia](#news-on)
- [More information on Verkazia](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Verkazia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.

It is not intended to provide practical advice on how to use Verkazia.

For practical information about using Verkazia, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Verkazia and what is it used for?

Verkazia is a medicine used to treat severe vernal keratoconjunctivitis (VKC), an allergic condition that affects the eye and mostly occurs seasonally, although in some patients symptoms can recur or persist all year round. It is used in children and adolescents from 4 to 18 years of age.

Because the number of patients with vernal keratoconjunctivitis is low, the disease is considered 'rare', and Verkazia was designated an 'orphan medicine' (a medicine used in rare diseases) on 6 April 2006.

Verkazia contains the active substance ciclosporin.

## How is Verkazia used?

Verkazia can only be obtained with a prescription and treatment must be started by a healthcare professional qualified in ophthalmology (eye medicine).

Verkazia is available as eye drops. The recommended dose is 1 drop 4 times a day in each affected eye, during VKC season. If symptoms persist after the end of the season, Verkazia can continue to be used at the recommended dose until symptoms are under control and at a reduced dose (1 drop twice a day) thereafter.

For further information, see the package leaflet.

## How does Verkazia work?

The active substance in Verkazia, ciclosporin, blocks cells of the immune system (the body's natural defences) that are involved in the processes that cause the allergic reaction and inflammation in patients with VKC. Applying it directly to the eye reduces eye inflammation but limits its effects elsewhere in the body.

## What benefits of Verkazia have been shown in studies?

Verkazia reduces damage to the cornea (layer in the front of the eye) in most patients with VKC as shown by improvements in 'corneal fluorescence staining' (CFS) scores (a standard measure of corneal health).

In a main study involving 169 children and adolescents with severe VKC, 55% of patients treated with Verkazia achieved CFS improvements of 50% or more, without the need of other medications, after 4 months, compared with around 28% of patients receiving a dummy treatment. Symptoms such as itching, fluid or mucous discharge and light sensitivity also improved in patients treated with Verkazia to a greater extent than with the dummy treatment. Some of the patients were treated for an additional 8 months; this extension study showed that the benefits of Verkazia were maintained with continued use for up to 12 months.

## What are the risks associated with Verkazia?

The most common side effects with Verkazia are eye pain and itching, which may affect around 1 in 10 people. These symptoms usually occur when the drops are being put in the eyes and go away shortly after.

Verkazia must not be used in patients with active or suspected infections in or around the eye.

For the full list of all side effects and restrictions with Verkazia, see the package leaflet.

## Why is Verkazia approved?

Verkazia has been shown to be effective at improving the condition of the cornea and reducing the symptoms of the disease. Side effects are mostly mild and disappear shortly after application of the medicine. The European Medicines Agency therefore decided that Verkazia's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Verkazia?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Verkazia have been included in the summary of product characteristics and the package leaflet.

## Other information about Verkazia

The European Commission granted a marketing authorisation valid throughout the European Union for Verkazia on 6 July 2018.

For more information about treatment with Verkazia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Verkazia : EPAR - Summary for the public

Reference Number: EMA/476178/2017

English (EN) (76.1 KB - PDF)

**First published:** 12/07/2018

**Last updated:** 12/07/2018

[View](/en/documents/overview/verkazia-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-846)

български (BG) (121.64 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/bg/documents/overview/verkazia-epar-summary-public_bg.pdf)

español (ES) (99.65 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/es/documents/overview/verkazia-epar-summary-public_es.pdf)

čeština (CS) (118.51 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/cs/documents/overview/verkazia-epar-summary-public_cs.pdf)

dansk (DA) (99.6 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/da/documents/overview/verkazia-epar-summary-public_da.pdf)

Deutsch (DE) (99.63 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/de/documents/overview/verkazia-epar-summary-public_de.pdf)

eesti keel (ET) (98.35 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/et/documents/overview/verkazia-epar-summary-public_et.pdf)

ελληνικά (EL) (122.43 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/el/documents/overview/verkazia-epar-summary-public_el.pdf)

français (FR) (99.92 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/fr/documents/overview/verkazia-epar-summary-public_fr.pdf)

hrvatski (HR) (112.63 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/hr/documents/overview/verkazia-epar-summary-public_hr.pdf)

italiano (IT) (99.6 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/it/documents/overview/verkazia-epar-summary-public_it.pdf)

latviešu valoda (LV) (126.52 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/lv/documents/overview/verkazia-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (116.9 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/lt/documents/overview/verkazia-epar-summary-public_lt.pdf)

magyar (HU) (114.3 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/hu/documents/overview/verkazia-epar-summary-public_hu.pdf)

Malti (MT) (130.97 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/mt/documents/overview/verkazia-epar-summary-public_mt.pdf)

Nederlands (NL) (100.11 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/nl/documents/overview/verkazia-epar-summary-public_nl.pdf)

polski (PL) (119.23 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/pl/documents/overview/verkazia-epar-summary-public_pl.pdf)

português (PT) (99.53 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/pt/documents/overview/verkazia-epar-summary-public_pt.pdf)

română (RO) (116.5 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/ro/documents/overview/verkazia-epar-summary-public_ro.pdf)

slovenčina (SK) (116.79 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/sk/documents/overview/verkazia-epar-summary-public_sk.pdf)

slovenščina (SL) (112.12 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/sl/documents/overview/verkazia-epar-summary-public_sl.pdf)

Suomi (FI) (98.78 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/fi/documents/overview/verkazia-epar-summary-public_fi.pdf)

svenska (SV) (98.95 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

12/07/2018

[View](/sv/documents/overview/verkazia-epar-summary-public_sv.pdf)

Verkazia : EPAR - Risk-management-plan summary

English (EN) (317.67 KB - PDF)

**First published:** 10/07/2020

**Last updated:** 25/04/2023

[View](/en/documents/rmp-summary/verkazia-epar-risk-management-plan-summary_en.pdf)

## Product information

Verkazia : EPAR - Product Information

English (EN) (509.26 KB - PDF)

**First published:** 12/07/2018

**Last updated:** 25/04/2023

[View](/en/documents/product-information/verkazia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-959)

български (BG) (532.61 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/bg/documents/product-information/verkazia-epar-product-information_bg.pdf)

español (ES) (452.18 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/es/documents/product-information/verkazia-epar-product-information_es.pdf)

čeština (CS) (502.64 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/cs/documents/product-information/verkazia-epar-product-information_cs.pdf)

dansk (DA) (460.96 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/da/documents/product-information/verkazia-epar-product-information_da.pdf)

Deutsch (DE) (458.57 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/de/documents/product-information/verkazia-epar-product-information_de.pdf)

eesti keel (ET) (455.86 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/et/documents/product-information/verkazia-epar-product-information_et.pdf)

ελληνικά (EL) (533.26 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/el/documents/product-information/verkazia-epar-product-information_el.pdf)

français (FR) (512.58 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/fr/documents/product-information/verkazia-epar-product-information_fr.pdf)

hrvatski (HR) (522.22 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/hr/documents/product-information/verkazia-epar-product-information_hr.pdf)

íslenska (IS) (457.63 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/is/documents/product-information/verkazia-epar-product-information_is.pdf)

italiano (IT) (457.82 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/it/documents/product-information/verkazia-epar-product-information_it.pdf)

latviešu valoda (LV) (499.93 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/lv/documents/product-information/verkazia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (538.67 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/lt/documents/product-information/verkazia-epar-product-information_lt.pdf)

magyar (HU) (518.04 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/hu/documents/product-information/verkazia-epar-product-information_hu.pdf)

Malti (MT) (537.92 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/mt/documents/product-information/verkazia-epar-product-information_mt.pdf)

Nederlands (NL) (417.84 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/nl/documents/product-information/verkazia-epar-product-information_nl.pdf)

norsk (NO) (482.09 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/no/documents/product-information/verkazia-epar-product-information_no.pdf)

polski (PL) (526.95 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/pl/documents/product-information/verkazia-epar-product-information_pl.pdf)

português (PT) (466.09 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/pt/documents/product-information/verkazia-epar-product-information_pt.pdf)

română (RO) (509.4 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/ro/documents/product-information/verkazia-epar-product-information_ro.pdf)

slovenčina (SK) (520.84 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/sk/documents/product-information/verkazia-epar-product-information_sk.pdf)

slovenščina (SL) (509.89 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/sl/documents/product-information/verkazia-epar-product-information_sl.pdf)

Suomi (FI) (393.22 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/fi/documents/product-information/verkazia-epar-product-information_fi.pdf)

svenska (SV) (442.79 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

25/04/2023

[View](/sv/documents/product-information/verkazia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0021 31/03/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Verkazia : EPAR - All Authorised presentations

English (EN) (28.02 KB - PDF)

**First published:** 12/07/2018

**Last updated:** 08/12/2021

[View](/en/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-63)

български (BG) (38.68 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/bg/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_bg.pdf)

español (ES) (87.05 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/es/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.26 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/cs/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (34.38 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/da/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34.27 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/de/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (32.67 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/et/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.57 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/el/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_el.pdf)

français (FR) (40.31 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/fr/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.11 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/hr/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (33.41 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/is/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (31.78 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/it/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.22 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/lv/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.97 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/lt/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.49 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/hu/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.24 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/mt/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (32.4 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/nl/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.75 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/no/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.18 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/pl/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_pl.pdf)

português (PT) (33.33 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/pt/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.21 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/ro/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (37.58 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/sk/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.8 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/sl/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (31.57 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/fi/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.66 KB - PDF)

**First published:**

12/07/2018

**Last updated:**

08/12/2021

[View](/sv/documents/all-authorised-presentations/verkazia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Verkazia Active substance ciclosporin International non-proprietary name (INN) or common name ciclosporin Therapeutic area (MeSH)

- Conjunctivitis
- Keratitis

Anatomical therapeutic chemical (ATC) code S01XA18

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.

## Authorisation details

EMA product number EMEA/H/C/004411

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Santen Oy

Niittyhaankatu 20

Opinion adopted 20/07/2017 Marketing authorisation issued 06/07/2018 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Verkazia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.33 KB - PDF)

**First published:** 25/04/2019

**Last updated:** 25/04/2023

[View](/en/documents/procedural-steps-after/verkazia-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Verkazia : EPAR - Public assessment report

Adopted

Reference Number: EMA/505143/2017

English (EN) (1.75 MB - PDF)

**First published:** 12/07/2018

**Last updated:** 12/07/2018

[View](/en/documents/assessment-report/verkazia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Verkazia

Reference Number: EMA/CHMP/372110/2017

English (EN) (68.05 KB - PDF)

**First published:** 21/07/2017

**Last updated:** 21/07/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-verkazia_en.pdf)

#### News on Verkazia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2017) 21/07/2017

[New medicine for rare form of eye allergy in children and teenagers](/en/news/new-medicine-rare-form-eye-allergy-children-teenagers) 21/07/2017

#### More information on Verkazia

- [EU/3/06/360 - orphan designation for treatment of vernal keratoconjunctivitis](/en/medicines/human/orphan-designations/eu-3-06-360)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/04/2023

## Share this page

[Back to top](#main-content)